PDLIM7 and nasopharyngeal carcinoma: Additionally, a phase II study (NCT03648697) is assessing the safety and tolerability of LMP1, LMP2 and EBNA1-specific TCRs (YT-E001) in HLA-A02:01-/24:02-/11:01-positive recurrent or metastatic NPC patients.